Entropy Neurodynamics Director Lifts Stake via $100,000 Share Placement

Tryptamine Therapeutics ( (AU:ENP) ) has issued an update.

Entropy Neurodynamics Limited has disclosed a change in director Chris Ntoumenopoulos’s indirect holdings following an allotment of placement shares approved by shareholders. The transaction saw Ntoumenopoulos acquire 2,941,176 additional ordinary fully paid shares for $100,000, increasing his indirect stake held through associated entities and signalling further director-aligned capital support for the company.

After the placement, Ntoumenopoulos’s indirect holding of ordinary shares rose to 5,441,176, alongside substantial existing option positions across multiple series with varying exercise prices and maturities. The director’s increased exposure underscores continued insider confidence in the company’s prospects and modestly strengthens the alignment between board and shareholder interests without altering overall control dynamics.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited, associated with Tryptamine Therapeutics, is an ASX-listed company operating in the biotechnology and neuropharmaceuticals sector. The company is focused on developing therapies that leverage neurodynamics and tryptamine-based approaches, targeting neurological and mental health indications in emerging therapeutic markets.

Average Trading Volume: 2,293,449

Technical Sentiment Signal: Sell

Current Market Cap: A$47.3M

For a thorough assessment of ENP stock, go to TipRanks’ Stock Analysis page.